RAD51B in Familial Breast Cancer
- PMID: 27149063
- PMCID: PMC4858276
- DOI: 10.1371/journal.pone.0153788
RAD51B in Familial Breast Cancer
Abstract
Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 x 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 x 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.
Conflict of interest statement
References
-
- Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40: 17–22. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- R01 CA176785/CA/NCI NIH HHS/United States
- UM1 CA164920/CA/NCI NIH HHS/United States
- 16565/CRUK_/Cancer Research UK/United Kingdom
- CAPMC/ CIHR/Canada
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- R01 CA100374/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
- P50 CA116201/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- U19 CA148112/CA/NCI NIH HHS/United States
- U01 CA098758/CA/NCI NIH HHS/United States
- U01 CA116167/CA/NCI NIH HHS/United States
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- U19 CA148537/CA/NCI NIH HHS/United States
- R01 CA116167/CA/NCI NIH HHS/United States
- C1287/A12014/CRUK_/Cancer Research UK/United Kingdom
- R01 CA063464/CA/NCI NIH HHS/United States
- U01 CA063464/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- R01 CA054281/CA/NCI NIH HHS/United States
- R01 CA132839/CA/NCI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- 10119/CRUK_/Cancer Research UK/United Kingdom
- C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
- 10118/CRUK_/Cancer Research UK/United Kingdom
- U01 CA164973/CA/NCI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- 16561/CRUK_/Cancer Research UK/United Kingdom
- 10124/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases